ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.11
+0.97%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.08
From 52W high−52.95%
Volume1.24M
Market cap$294.43M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.08
From 52W high
−52.95%
Volume
1.24M
Market cap
$294.43M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
28.5
MomentumView details →
1D Return
+0.97%
YTD Return
+125.21%
SummaryUpdated Jun 1, 2026
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. The company went public in April 2020 and focuses on discovering and developing small molecule therapeutics specifically designed to treat various forms of cancer. Zentalis operates in the highly specialized field of precision oncology, where it develops targeted therapies that aim to disrupt specific molecular pathways involved in cancer cell growth and survival.
Similar companies
Latest newsMore news →